Aberrations in genes and molecular pathways, include IDH1/IDH2 and H3.1/H3.3 mutation or loss of TP53 tumor suppressor gene, can be used together with histopathological findings for gliomas classification (8, 9). The gene discussed is IDH1; the disease is central nervous system cancer.